Decoy Therapeutics Inc. Cash Flow Statement
DCOY|7 years of annual SEC 10-K data (FY2016-FY2022)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Decoy Therapeutics Inc. used $10M in operating cash flow in FY2022.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|
| Net Income | -$12.8M | -$7.4M | -$6.9M | -$1.7M | -$39.5M | -$29.1M | -$8.0M |
| Depreciation & Amortization | $19.2K | $18.1K | $127.4K | $16.9K | $277.2K | $49.9K | $12.0K |
| Operating Cash Flow | -$10.2M | -$10.3M | -$11.6M | $4.2M | -$32.1M | -$20.7M | -$6.5M |
| Capital Expenditures | - | $2.6K | $0 | - | $559.4K | $265.6K | $76.1K |
| Free Cash Flow | - | -$10.3M | -$11.6M | - | -$32.6M | -$21.0M | -$6.6M |
| Share Buybacks | - | - | - | $615.0K | - | - | - |
| Dividends Paid | - | - | $133.6K | $0 | - | - | - |
| FCF Margin | - | -197.1% | -334.2% | - | -3226.7% | - | - |